Efficacy and Tolerance of Therapeutic Apheresis in Paediatric Neurology: a French Multicenter Study

lobal neurological efficacy of therapeutic apheresis as assessed by modified rankin score Modifed Rankin score, ranging from 0 (no symptoms) to 6 (death)

tIncidence of therapeutic apheresis adverse events as assessed by low blood tension rate, transfusion rate, infection rate, hypocalcaemia rate, thrombosis rate, allergy rate, anemia rate, hemostasis disorders rate).

Incidence of adjuvant treatments (corticosteroid therapy, immunoglobulins, immunosuppressants),

Incidence of hospitalization in intensive care, intubation rate

number of procedures

exchanged volume (in plasma volume percentage) for each procedure

type of separation et number of participants with ttt-related advesre events

type of replacement solution (isotonic saline, albumin, fresh frozen plasma)

rate of arterial hypotension (< age standards and and requiring isotonic saline bolus, for each patient and for procedure)

rate of hypocalcemia (ionized calcium <1,1 mmol/L, for each patient and for each procedure)

rate of hypoalbuminemiafor for each patient and for each procedure)

rate of thrombosis (confirmed by a CT scan or ultrasound, for each patient)

rate of infections related catheter (for each patient)

rate of allergics reactions (for each patient and for each procedure)

rate of anemia (Hb < 7,0 g/dL, for each patient)

rate of transfusion (for each patient)

rate of haemostasis disorder (platelets < 100 <G/L ; TQ < 40 % ; fibrinogen < 1 G/L ; (for each patient and for each procedure)

rate of death